FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

Public Health News - Page 4 of 101 - SciTechDaily

FDA efficiency for approval process of COVID-19 therapeutics

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug

FDA Faces Hard Decisions After Fast-Tracking Unproven Drugs

FDA's accelerated drug approvals often lack confirmatory evidence

SEC Filing Vistagen Therapeutics, Inc

SEC Filing Vistagen Therapeutics, Inc

FDA's accelerated drug approvals often lack confirmatory evidence

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for